Earnings
Operating income amounted to €(4,159) K as of June 30, 2017 compared to €(3,711) K as of June 30, 2016.
Gilead continues to see serious revenue declines in its hepatitis C marketshare, a space it has dominated for several years.
The company reported record third quarter 2017 revenue of $122.6 million
Biogen released its third-quarter financials yesterday, showing total revenues of $3.1B for the quarter, a 4 percent gain compared to the same period the previous year.
In addition to the layoffs, the company is also looking to divest its Infectious Disease Business.
Net sales of DARZALEX in the third quarter of 2017 totaled USD 317 million.
AxoGen management will host an investment-community conference call and webcast following the release at 4:30 p.m. ET.
Osprey Medical today released its Appendix 4C – Quarterly Cashflow Report for the period ending 30 September 2017.
PRESS RELEASES